Selenium homeostasis and induction of thioredoxin reductase during long term selenite supplementation in the rat

Journal of Trace Elements in Medicine and Biology

Volumn 25, Issue 4, 2011, Pages 254-259

  Erkhembayar, Suvd ^a   Mollbrink, Annelie ^a   Eriksson, Malin ^a   Larsen, Erik H ^b   Eriksson, Lennart C ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Rat liver; Selenium homeostasis; Thioredoxin reductase

Indexed keywords

DRINKING WATER; SELENIUM; SODIUM SELENITE; THIOREDOXIN REDUCTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CANCER PREVENTION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DOSE COMPARISON; ENZYME ACTIVITY; GENE EXPRESSION; LIVER LEVEL; LIVER WEIGHT; LONG TERM EXPOSURE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT;

ANIMALS; BODY WEIGHT; DIETARY SUPPLEMENTS; ENZYME INDUCTION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HOMEOSTASIS; LIVER; MALE; ORGAN SIZE; RATS; RATS, INBRED F344; RNA, MESSENGER; SELENIUM; THIOREDOXIN-DISULFIDE REDUCTASE; TIME FACTORS;

RATTUS;

EID: 82855172058     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2011.09.002     Document Type: Article

References (38)

1. Whanger P.D. Selenium and its relationship to cancer: an update. Br J Nutr 2004, 91:11-28.
2. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 1998, 128:1845-1854.
3. Clark L.C., Combs G.F., Turnbull B.W., Slate E.H., Chalker D.K., Chow J., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996, 276:1957-1963.
4. Bjorkhem-Bergman L., Torndal U.B., Eken S., Nystrom C., Capitanio A., Larsen E.H., et al. Selenium prevents tumor development in a rat model for chemical carcinogenesis. Carcinogenesis 2005, 26:125-131.
5. Ren X., Bjornstedt M., Shen B., Ericson M.L., Holmgren A. Mutagenesis of structural half-cystine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione. Biochemistry 1993, 32:9701-9708.
6. Arner E.S., Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000, 267:6102-6109.
7. Becker K., Gromer S., Schirmer R.H., Muller S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem 2000, 267:6118-6125.
8. Urig S., Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol 2006, 16:452-465.
9. Bjorkhem L., Teclebrhan H., Kesen E., Olsson J.M., Eriksson L.C., Bjornstedt M. Increased levels of cytosolic thioredoxin reductase activity and mRNA in rat liver nodules. J Hepatol 2001, 35:259-264.
10. 77Se in isotopically enriched human samples by ICP-dynamic reaction cell-MS. J Anal At Spectrom 2003, 18:317-322.
11. Holmgren A., Björnstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol 1995, 252:199-208.
12. Brozmanova J., Manikova D., Vlckova V., Chovanec M. Selenium: a double-edged sword for defense and offence in cancer. Arch Toxicol 2010, 84:919-938.
13. Behne D., Wolters W. Distribution of selenium and glutathione peroxidase in the rat. J Nutr 1983, 113:456-461.
14. Tsen C.C., Tappel A.L. Catalytic oxidation of glutathione and other sulfhydryl compounds by selenite. J Biol Chem 1958, 233:1230-1232.
15. Kryukov G.V., Castellano S., Novoselov S.V., Lobanov A.V., Zehtab O., Guigo R., et al. Characterization of mammalian selenoproteomes. Science 2003, 300:1439-1443.
16. Wastney M.E., Combs G.F., Canfield W.K., Taylor P.R., Patterson K.Y., Hill A.D., et al. A human model of selenium that integrates metabolism from selenite and selenomethionine. J Nutr 2011, 141:708-717.
17. Thomson C.D., Stewart R.D. Metabolic studies of (75Se)selenomethionine and (75Se)selenite in the rat. Br J Nutr 1973, 30:139-147.
18. Behne D., Alber D., Kyriakopoulos A. Effects of long-term selenium yeast supplementation on selenium status studied in the rat. J Trace Elem Med Biol 2009, 23:258-264.
19. Janghorbani M., Rockway S., Mooers C.S., Roberts E.M., Ting B.T., Sitrin M.D. Effect of chronic selenite supplementation on selenium excretion and organ accumulation in rats. J Nutr 1990, 120:274-279.
20. Kobayashi Y., Ogra Y., Ishiwata K., Takayama H., Aimi N., Suzuki K.T. Selenosugars are key and urinary metabolites for selenium excretion within the required to low-toxic range. Proc Natl Acad Sci U S A 2002, 99:15932-15936.
21. Mc C.K., Portman O.W. Toxicity of dimethyl selenide in the rat and mouse. Proc Soc Exp Biol Med 1952, 79:230-231.
22. Jaffe W.G., Mondragon M.C. Adaptation of rats to selenium intake. J Nutr 1969, 97:431-436.
23. Suzuki K.T., Kurasaki K., Okazaki N., Ogra Y. Selenosugar and trimethylselenonium among urinary Se metabolites: dose- and age-related changes. Toxicol Appl Pharmacol 2005, 206:1-8.
24. Hawkes W.C., Wilhelmsen E.C., Tappel A.L. Abundance and tissue distribution of selenocysteine-containing proteins in the rat. J Inorg Biochem 1985, 23:77-92.
25. Berggren M.M., Mangin J.F., Gasdaka J.R., Powis G. Effect of selenium on rat thioredoxin reductase activity: increase by supranutritional selenium and decrease by selenium deficiency. Biochem Pharmacol 1999, 57:187-193.
26. Ganther H.E. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 1999, 20:1657-1666.
27. Lane H.W., Medina D. Selenium concentration and glutathione peroxidase activity in normal and neoplastic development of the mouse mammary gland. Cancer Res 1983, 43:1558-1561.
28. Behne D., Kyriakopoulos A. Effects of dietary selenium on the tissue concentrations of type I iodothyronine 5'-deiodinase and other selenoproteins. Am J Clin Nutr 1993, 57(2 (Suppl.)):310S-312S.
29. Berggren M., Gallegos A., Gasdaska J.R., Gasdaska P.Y., Warneke J., Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 1996, 16:3459-3466.
30. Lincoln D.T., Ali Emadi E.M., Tonissen K.F., Clarke F.M. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 2003, 23:2425-2433.
31. Kahlos K., Soini Y., Saily M., Koistinen P., Kakko S., Paakko P., et al. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer 2001, 95:198-204.
32. Soini Y., Kahlos K., Napankangas U., Kaarteenaho-Wiik R., Saily M., Koistinen P., et al. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 2001, 7:1750-1757.
33. Park J.H., Kim Y.S., Lee H.L., Shim J.Y., Lee K.S., Oh Y.J., et al. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 2006, 11:269-275.
34. Yoo M.H., Xu X.M., Carlson B.A., Gladyshev V.N., Hatfield D.L. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 2006, 281:13005-13008.
35. Gan L., Yang X.L., Liu Q., Xu H.B. Inhibitory effects of thioredoxin reductase antisense RNA on the growth of human hepatocellular carcinoma cells. J Cell Biochem 2005, 96:653-664.
36. Rundlof A.K., Arner E.S. Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid Redox Signal 2004, 6:41-52.
37. Olm E., Fernandes A.P., Hebert C., Rundlof A.K., Larsen E.H., Danielsson O., et al. Extracellular thiol-assisted selenium uptake dependent on the x(c)-cystine transporter explains the cancer-specific cytotoxicity of selenite. Proc Natl Acad Sci U S A 2009, 106:11400-11405.
38. Selenius M., Fernandes A.P., Brodin O., Bjornstedt M., Rundlof A.K. Treatment of lung cancer cells with cytotoxic levels of sodium selenite: effects on the thioredoxin system. Biochem Pharmacol 2008, 75:2092-2099.